ID   SV2C_RAT                Reviewed;         727 AA.
AC   Q9Z2I6;
DT   13-JUN-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   29-MAY-2024, entry version 147.
DE   RecName: Full=Synaptic vesicle glycoprotein 2C;
DE            Short=Synaptic vesicle protein 2C;
GN   Name=Sv2c;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], GLYCOSYLATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=9801366; DOI=10.1523/jneurosci.18-22-09269.1998;
RA   Janz R., Hofmann K., Suedhof T.C.;
RT   "SVOP, an evolutionarily conserved synaptic vesicle protein, suggests novel
RT   transport functions of synaptic vesicles.";
RL   J. Neurosci. 18:9269-9281(1998).
RN   [2]
RP   GLYCOSYLATION, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=10625067; DOI=10.1016/s0306-4522(99)00370-x;
RA   Janz R., Suedhof T.C.;
RT   "SV2C is a synaptic vesicle protein with an unusually restricted
RT   localization: anatomy of a synaptic vesicle protein family.";
RL   Neuroscience 94:1279-1290(1999).
RN   [3]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16306227; DOI=10.1242/jcs.02658;
RA   Iezzi M., Theander S., Janz R., Loze C., Wollheim C.B.;
RT   "SV2A and SV2C are not vesicular Ca2+ transporters but control glucose-
RT   evoked granule recruitment.";
RL   J. Cell Sci. 118:5647-5660(2005).
RN   [4]
RP   FUNCTION, AND INTERACTION WITH SYT1.
RX   PubMed=15866046; DOI=10.1016/j.mcn.2004.12.011;
RA   Schivell A.E., Mochida S., Kensel-Hammes P., Custer K.L., Bajjalieh S.M.;
RT   "SV2A and SV2C contain a unique synaptotagmin-binding site.";
RL   Mol. Cell. Neurosci. 29:56-64(2005).
RN   [5]
RP   FUNCTION AS BOTULINUM NEUROTOXIN TYPE A RECEPTOR (MICROBIAL INFECTION),
RP   SUBUNIT (MICROBIAL INFECTION), AND DOMAIN.
RX   PubMed=16543415; DOI=10.1126/science.1123654;
RA   Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., Chapman E.R.;
RT   "SV2 is the protein receptor for botulinum neurotoxin A.";
RL   Science 312:592-596(2006).
RN   [6]
RP   NOT A C.BOTULINUM NEUROTOXIN TYPE E RECEPTOR.
RX   PubMed=18815274; DOI=10.1091/mbc.e08-07-0765;
RA   Dong M., Liu H., Tepp W.H., Johnson E.A., Janz R., Chapman E.R.;
RT   "Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E
RT   into neurons.";
RL   Mol. Biol. Cell 19:5226-5237(2008).
RN   [7]
RP   FUNCTION AS C.BOTULINUM NEUROTOXIN TYPE F RECEPTOR (MICROBIAL INFECTION),
RP   AND SUBUNIT (MICROBIAL INFECTION).
RX   PubMed=19476346; DOI=10.1021/bi9002138;
RA   Fu Z., Chen C., Barbieri J.T., Kim J.J., Baldwin M.R.;
RT   "Glycosylated SV2 and gangliosides as dual receptors for botulinum
RT   neurotoxin serotype F.";
RL   Biochemistry 48:5631-5641(2009).
RN   [8]
RP   FUNCTION AS C.BOTULINUM NEUROTOXIN TYPES A AND F RECEPTOR (MICROBIAL
RP   INFECTION), AND SUBUNIT (MICROBIAL INFECTION).
RX   PubMed=19650874; DOI=10.1111/j.1471-4159.2009.06298.x;
RA   Rummel A., Haefner K., Mahrhold S., Darashchonak N., Holt M., Jahn R.,
RA   Beermann S., Karnath T., Bigalke H., Binz T.;
RT   "Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding
RT   site prior to stimulation-dependent uptake with botulinum neurotoxin F
RT   utilising the three isoforms of SV2 as second receptor.";
RL   J. Neurochem. 110:1942-1954(2009).
RN   [9]
RP   POSSIBLE FUNCTION AS C.BOTULINUM NEUROTOXIN TYPE D RECEPTOR (MICROBIAL
RP   INFECTION), AND SUBUNIT (MICROBIAL INFECTION).
RX   PubMed=21483489; DOI=10.1371/journal.ppat.1002008;
RA   Peng L., Tepp W.H., Johnson E.A., Dong M.;
RT   "Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides
RT   as receptors.";
RL   PLoS Pathog. 7:E1002008-E1002008(2011).
RN   [10]
RP   NOT RECEPTOR FOR C.BOTULINUM NEUROTOXIN TYPE D (MICROBIAL INFECTION).
RX   PubMed=21632541; DOI=10.1074/jbc.m111.254086;
RA   Kroken A.R., Karalewitz A.P., Fu Z., Kim J.J., Barbieri J.T.;
RT   "Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into
RT   neurons.";
RL   J. Biol. Chem. 286:26828-26837(2011).
RN   [11] {ECO:0007744|PDB:5JMC}
RP   X-RAY CRYSTALLOGRAPHY (2.64 ANGSTROMS) OF 455-577, FUNCTION AS C.BOTULINUM
RP   NEUROTOXIN TYPE A RECEPTOR (MICROBIAL INFECTION), SUBUNIT (MICROBIAL
RP   INFECTION), MUTAGENESIS OF ASN-559, AND GLYCOSYLATION AT ASN-559.
RX   PubMed=27294781; DOI=10.1038/nsmb.3245;
RA   Yao G., Zhang S., Mahrhold S., Lam K.H., Stern D., Bagramyan K., Perry K.,
RA   Kalkum M., Rummel A., Dong M., Jin R.;
RT   "N-linked glycosylation of SV2 is required for binding and uptake of
RT   botulinum neurotoxin A.";
RL   Nat. Struct. Mol. Biol. 23:656-662(2016).
CC   -!- FUNCTION: Plays a role in the control of regulated secretion in neural
CC       and endocrine cells, enhancing selectively low-frequency
CC       neurotransmission. Positively regulates vesicle fusion by maintaining
CC       the readily releasable pool of secretory vesicles.
CC       {ECO:0000269|PubMed:15866046, ECO:0000269|PubMed:16306227}.
CC   -!- FUNCTION: (Microbial infection) Receptor for C.botulinum neurotoxin
CC       type A (BoNT/A, botA); the toxin binds Sv2c via extracellular loop 4
CC       (PubMed:16543415, PubMed:27294781). Restores uptake of BoNT/A in rat
CC       cells that are deleted for SV2 receptor (PubMed:16543415,
CC       PubMed:18815274). {ECO:0000269|PubMed:16543415,
CC       ECO:0000269|PubMed:19650874, ECO:0000269|PubMed:27294781}.
CC   -!- FUNCTION: (Microbial infection) Possible receptor for C.botulinum
CC       neurotoxin type D (BoNT/D, botD); BoNT/D does not bind to extracellular
CC       loop 4 as do BoNT/A and BoNT/E (PubMed:21483489). Another group does
CC       not find a convincing interaction with SV2 (PubMed:21632541).
CC       {ECO:0000269|PubMed:21483489, ECO:0000269|PubMed:21632541}.
CC   -!- FUNCTION: (Microbial infection) Receptor for C.botulinum neurotoxin
CC       type F (BoNT/F); binding requires glycosylation of Asn-573
CC       (PubMed:19476346, PubMed:19650874). {ECO:0000269|PubMed:19650874,
CC       ECO:0000305|PubMed:19476346}.
CC   -!- SUBUNIT: Interacts with SYT1 in a calcium-dependent manner.
CC       {ECO:0000269|PubMed:15866046}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with C.botulinum neurotoxin
CC       type A (BoNT/A, botA). {ECO:0000269|PubMed:16543415,
CC       ECO:0000269|PubMed:19650874, ECO:0000269|PubMed:21483489,
CC       ECO:0000269|PubMed:27294781}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with C.botulinum neurotoxin
CC       type F (BoNT/F) (PubMed:19650874). Interaction requires glycosylation
CC       of SV2 proteins (PubMed:19476346, PubMed:19650874).
CC       {ECO:0000269|PubMed:19650874, ECO:0000305|PubMed:19476346}.
CC   -!- INTERACTION:
CC       Q9Z2I6; P0DPI0: botA; Xeno; NbExp=12; IntAct=EBI-8178859, EBI-8178893;
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle, secretory vesicle, synaptic
CC       vesicle membrane {ECO:0000269|PubMed:10625067,
CC       ECO:0000269|PubMed:16306227}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:10625067, ECO:0000269|PubMed:16306227}.
CC       Note=Enriched in small synaptic vesicles and adrenal microsomes, not
CC       present in chromaffin granules. Associated with both insulin granules
CC       and synaptic-like microvesicles in insulin-secreting cells of the
CC       pancreas.
CC   -!- TISSUE SPECIFICITY: Expressed at high levels in very few brain areas
CC       including the striatum, midbrain and hindbrain, and in the olfactory
CC       bulb. Expressed at lower levels in cerebrum, hippocampus and cerebellum
CC       (at protein level). Mainly expressed in brain; also detected in lung,
CC       liver, kidney. {ECO:0000269|PubMed:10625067,
CC       ECO:0000269|PubMed:9801366}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:10625067,
CC       ECO:0000269|PubMed:27294781, ECO:0000269|PubMed:9801366}.
CC   -!- SIMILARITY: Belongs to the major facilitator superfamily.
CC       {ECO:0000305}.
CC   -!- CAUTION: The use of this protein as a coreceptor for C.botulinum type D
CC       (BoNT/D, botD) is controversial. In double SV2A/SV2B knockout mice
CC       BoNT/D does not degrade its synaptobrevin target; introducing SV2A,
CC       SV2B or SV2C restores target cleavage (PubMed:21483489). However
CC       another group does not find a convincing interaction with SV2
CC       (PubMed:21632541). {ECO:0000269|PubMed:21483489,
CC       ECO:0000269|PubMed:21632541}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF060174; AAC78628.1; -; mRNA.
DR   RefSeq; NP_113781.1; NM_031593.1.
DR   RefSeq; XP_017446285.1; XM_017590796.1.
DR   PDB; 5JMC; X-ray; 2.64 A; B/D/F/H=455-577.
DR   PDBsum; 5JMC; -.
DR   AlphaFoldDB; Q9Z2I6; -.
DR   SMR; Q9Z2I6; -.
DR   IntAct; Q9Z2I6; 1.
DR   MINT; Q9Z2I6; -.
DR   STRING; 10116.ENSRNOP00000024459; -.
DR   GlyCosmos; Q9Z2I6; 5 sites, No reported glycans.
DR   GlyGen; Q9Z2I6; 5 sites.
DR   iPTMnet; Q9Z2I6; -.
DR   PhosphoSitePlus; Q9Z2I6; -.
DR   PaxDb; 10116-ENSRNOP00000024459; -.
DR   Ensembl; ENSRNOT00000024459.7; ENSRNOP00000024459.3; ENSRNOG00000018094.7.
DR   Ensembl; ENSRNOT00055048390; ENSRNOP00055039787; ENSRNOG00055027955.
DR   Ensembl; ENSRNOT00060050561; ENSRNOP00060042078; ENSRNOG00060029133.
DR   Ensembl; ENSRNOT00065042223; ENSRNOP00065034527; ENSRNOG00065024595.
DR   GeneID; 29643; -.
DR   KEGG; rno:29643; -.
DR   UCSC; RGD:619718; rat.
DR   AGR; RGD:619718; -.
DR   CTD; 22987; -.
DR   RGD; 619718; Sv2c.
DR   eggNOG; KOG0255; Eukaryota.
DR   GeneTree; ENSGT00950000182940; -.
DR   HOGENOM; CLU_001265_46_15_1; -.
DR   InParanoid; Q9Z2I6; -.
DR   OMA; INCYFED; -.
DR   OrthoDB; 2615066at2759; -.
DR   PhylomeDB; Q9Z2I6; -.
DR   TreeFam; TF324824; -.
DR   PRO; PR:Q9Z2I6; -.
DR   Proteomes; UP000002494; Chromosome 2.
DR   Bgee; ENSRNOG00000018094; Expressed in cerebellum and 9 other cell types or tissues.
DR   GO; GO:0098691; C:dopaminergic synapse; ISO:RGD.
DR   GO; GO:0008021; C:synaptic vesicle; IDA:RGD.
DR   GO; GO:0030672; C:synaptic vesicle membrane; IDA:SynGO.
DR   GO; GO:0022857; F:transmembrane transporter activity; IEA:InterPro.
DR   GO; GO:0007268; P:chemical synaptic transmission; IEA:InterPro.
DR   GO; GO:0006836; P:neurotransmitter transport; IEA:UniProtKB-KW.
DR   GO; GO:2000300; P:regulation of synaptic vesicle exocytosis; ISO:RGD.
DR   CDD; cd17440; MFS_SV2C; 1.
DR   Gene3D; 2.160.20.80; E3 ubiquitin-protein ligase SopA; 1.
DR   Gene3D; 1.20.1250.20; MFS general substrate transporter like domains; 2.
DR   InterPro; IPR001646; 5peptide_repeat.
DR   InterPro; IPR011701; MFS.
DR   InterPro; IPR020846; MFS_dom.
DR   InterPro; IPR005828; MFS_sugar_transport-like.
DR   InterPro; IPR036259; MFS_trans_sf.
DR   InterPro; IPR005829; Sugar_transporter_CS.
DR   InterPro; IPR022308; SV2.
DR   NCBIfam; TIGR01299; synapt_SV2; 1.
DR   PANTHER; PTHR23511; SYNAPTIC VESICLE GLYCOPROTEIN 2; 1.
DR   PANTHER; PTHR23511:SF6; SYNAPTIC VESICLE GLYCOPROTEIN 2C; 1.
DR   Pfam; PF07690; MFS_1; 1.
DR   Pfam; PF13599; Pentapeptide_4; 1.
DR   Pfam; PF00083; Sugar_tr; 1.
DR   SUPFAM; SSF103473; MFS general substrate transporter; 2.
DR   SUPFAM; SSF141571; Pentapeptide repeat-like; 1.
DR   PROSITE; PS50850; MFS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cytoplasmic vesicle; Glycoprotein; Membrane;
KW   Neurotransmitter transport; Phosphoprotein; Receptor; Reference proteome;
KW   Synapse; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..727
FT                   /note="Synaptic vesicle glycoprotein 2C"
FT                   /id="PRO_0000239773"
FT   TOPO_DOM        1..154
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        155..175
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        176..191
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        192..212
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        213..226
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        227..247
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        248
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        249..269
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        270..280
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        281..301
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        302..320
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        321..341
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        342..437
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        438..458
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        459..578
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:16543415"
FT   TRANSMEM        579..599
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        600..609
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        610..630
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        631..636
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        637..657
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        658..670
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        671..693
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        694..697
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        698..716
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        717..727
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          1..57
FT                   /note="Interaction with SYT1"
FT                   /evidence="ECO:0000269|PubMed:15866046"
FT   REGION          22..120
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          529..566
FT                   /note="(Microbial infection) C.botulinum neurotoxin type A-
FT                   binding"
FT                   /evidence="ECO:0000269|PubMed:16543415,
FT                   ECO:0000269|PubMed:27294781"
FT   COMPBIAS        22..51
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        73..91
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         75
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7L0J3"
FT   MOD_RES         76
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7L0J3"
FT   MOD_RES         79
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7L0J3"
FT   MOD_RES         466
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JIS5"
FT   CARBOHYD        480
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        484
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        534
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        559
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305|PubMed:27294781"
FT   CARBOHYD        565
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   MUTAGEN         559
FT                   /note="N->A: Loss of one glycosylation site. No effect on
FT                   C.botulinum neurotoxin type A (BoNT/A, botA) binding, but
FT                   reduces the uptake of BoNT/A."
FT                   /evidence="ECO:0000269|PubMed:27294781"
FT   STRAND          478..480
FT                   /evidence="ECO:0007829|PDB:5JMC"
FT   STRAND          488..494
FT                   /evidence="ECO:0007829|PDB:5JMC"
FT   STRAND          496..499
FT                   /evidence="ECO:0007829|PDB:5JMC"
FT   STRAND          501..504
FT                   /evidence="ECO:0007829|PDB:5JMC"
FT   STRAND          506..509
FT                   /evidence="ECO:0007829|PDB:5JMC"
FT   STRAND          511..514
FT                   /evidence="ECO:0007829|PDB:5JMC"
FT   STRAND          516..519
FT                   /evidence="ECO:0007829|PDB:5JMC"
FT   STRAND          521..524
FT                   /evidence="ECO:0007829|PDB:5JMC"
FT   STRAND          526..529
FT                   /evidence="ECO:0007829|PDB:5JMC"
FT   STRAND          531..534
FT                   /evidence="ECO:0007829|PDB:5JMC"
FT   STRAND          536..539
FT                   /evidence="ECO:0007829|PDB:5JMC"
FT   STRAND          541..545
FT                   /evidence="ECO:0007829|PDB:5JMC"
FT   HELIX           549..551
FT                   /evidence="ECO:0007829|PDB:5JMC"
FT   STRAND          552..554
FT                   /evidence="ECO:0007829|PDB:5JMC"
FT   STRAND          556..562
FT                   /evidence="ECO:0007829|PDB:5JMC"
SQ   SEQUENCE   727 AA;  82249 MW;  4C154C69341D8DB7 CRC64;
     MEDSYKDRTS LMKGAKDIAK EVKKQTVKKV NQAVDRAQDE YTQRSYSRFQ DEDDDDDYYP
     PGETYSGEAN DDEGSSEATE GHDEEDEIYE GEYQGIPSTN QGKDSIVSVG QPKGDEYKDR
     RELESERRAD EEELAQQYEL IIQECGHGRF QWALFFVLGM ALMADGVEVF VVGFVLPSAE
     TDLCIPNSGS GWLGSIVYLG MMVGAFFWGG LADKVGRKQS LLICMSVNGF FAFLSSFVQG
     YGFFLLCRLL SGFGIGGAIP TVFSYFAEVL AREKRGEHLS WLCMFWMIGG IYASAMAWAI
     IPHYGWSFSM GSAYQFHSWR VFVIVCALPC VSSVVALTFM PESPRFLLEV GKHDEAWMIL
     KLIHDTNMRA RGQPEKVFTV NKIKTPKQID ELIEIESDTG TWYRRCFVRI RTELYGIWLT
     FMRCFNYPVR ENTIKLTIVW FTLSFGYYGL SVWFPDVIKH LQSDEYALLT RNVQKDKYAN
     FSINFTMENQ VHTGMEYDNG RFLGVKFKSV TFKDSVFKSC TFDDVTSVNT YFKNCTFIDT
     LFENTDFEPY KFIDSEFQNC SFLHNKTGCQ ITFDDDYSAY WIYFVNFLGT LAVLPGNIVS
     ALLMDRIGRL TMLGGSMVLS GISCFFLWFG TSESMMIGML CLYNGLTISA WNSLDVVTVE
     LYPTDRRATG FGFLNALCKA AAVLGNLIFG SLVSITKAIP ILLASTVLVC GGLVGLRLPD
     TRTQVLM
//
